A combination of serotonin reuptake inhibitor antidepressants (prozac and stimulaton) with atypical antipsychotics (zyprexa and solian) reduced depression in patients with recurrent depressive disorders during 10 days. The effect was evenly distributed between 10, 20 and 40 days of treatment. Other symptoms had a peculiar dynamics depending on the therapy. By the end of the study, similar effects were achieved for all groups. The addition of antipsychotics to antidepressant treatment insignificantly increased the number of adverse events.

Download full-text PDF

Source

Publication Analysis

Top Keywords

combination serotonin
8
serotonin reuptake
8
reuptake inhibitor
8
inhibitor antidepressants
8
recurrent depressive
8
[the comparative
4
comparative study
4
study efficacy
4
efficacy combination
4
antidepressants antipsychotics
4

Similar Publications

Objective: To investigate the efficacy of Shengyang Yiwei Decoction (SYD) combined with selective serotonin reuptake inhibitor(SSRI) antidepressants on the total score and scores of factors of the Hamilton Rating Scale for Depression(HAMD-17) and somatic symptoms in patients with depression.

Methods: This was a retrospective study. One hundred and twenty patients with depression were treated in Hebei Provincial Mental Health Center between December 2020 and May 2022 and randomly divided into the experimental group and the control group, with 60 patients in each group.

View Article and Find Full Text PDF

Objective: This study aims to explore the therapeutic mechanism of Massa Medicata Fermentata (MMF) with different formulations on spleen deficiency constipation in mice by analyzing gastrointestinal hormones, D-xylose, intestinal microbiota, and intestinal enzyme activities.

Methods: A spleen deficiency constipation model was established using an oral administration of Sennae Folium decoction combined with controlled diet and water intake. After successful model establishment, the mice with spleen deficiency constipation were treated with MMF S1, S2, S3.

View Article and Find Full Text PDF

Purpose: To evaluate the risk of bleeding associated with the simultaneous administration of antidepressants (ADs) and direct oral anticoagulants (DOACs).

Methods: PubMed, Embase, and Scopus databases were searched for papers that focused on the concomitant administration of ADs and DOACs and presented data on the bleeding outcomes. The comparator group of interest consisted of subjects who received only DOACs.

View Article and Find Full Text PDF

The impact of borneolum on Citalopram hydrobromide pharmacokinetics and serotonin levels in the hypothalamus of conscious rats.

Nat Prod Res

January 2025

Engineering Research Center of Modern Preparation Technology of TCM of Ministry of Education, Innovation Research Institute of Traditional Chinese Medicine, Shanghai University of Traditional Chinese Medicine, Shanghai, China.

Borneolum (BO) is an effectiveness adjuvant in facilitating the transportation of central nervous system drugs to the brain by opening the blood-brain barrier (BBB). Citalopram hydrobromide (CIT-HBr), a widely prescribed serotonin (5-HT) reuptake inhibitor, restricts the efficacy due to the BBB, resulting in slow onset and systemic side effects. Enhancing CIT-HBr's efficacy through BO appears to be a promising approach.

View Article and Find Full Text PDF

Want AI Summaries of new PubMed Abstracts delivered to your In-box?

Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!